Sunridge Medical · Scottsdale, Arizona

Alternative Prostate Cancer Treatment

If you have prostate cancer, call us before making the next treatment decision. We can help.

We review stage, Grade Group, PSA trend, imaging, biomarkers, previous care and quality-of-life priorities to help clarify the right path.

Call Free: 1-800-923-7878 Tell Us About Your Diagnosis

New diagnoses, recurrence, advanced disease and second-opinion questions are welcome.

Talk With Our Prostate Cancer Patient Care Team

There is no charge to speak with our Patient Care Team about your prostate cancer diagnosis, ask practical questions and learn whether a physician consultation may be an appropriate next step.

Prefer to speak now?Call 1-800-923-7878This introductory call is free. It is not a medical consultation and does not establish a physician-patient relationship.

Integrative & Alternative Oncology · Prostate Cancer Care

Alternative Prostate Cancer Treatment: Integrative Care for Every Stage

Prostate cancer can range from a small, slow-growing tumor that may be monitored to an aggressive metastatic disease that needs prompt combination treatment. Sunridge Medical builds physician-directed integrative care around the biology of the cancer, the treatments already used and the life the patient wants to protect.

We welcome men who are newly diagnosed, considering active surveillance, preparing for surgery or radiation, receiving androgen-deprivation or systemic therapy, living with recurrent disease, or seeking more options for Stage 4 prostate cancer.

Request a Prostate Cancer Consultation →Call 1-800-923-7878

Prostate anatomy with MRI, pathology, molecular testing and PSMA imaging concepts

LocalizedRisk mattersStage, Grade Group, PSA, MRI and health shape whether monitoring or treatment is reasonable.

AdvancedMore than one lineHormone therapy, intensified systemic treatment, radioligand therapy and trials can be sequenced.

PrecisionTest the biologyInherited genetics, tumor DNA-repair genes, MSI/MMR and PSMA expression can change options.

Whole personProtect functionStrength, bone, metabolic, urinary, sexual and emotional health belong in the plan.

The First Decision

Understand the Exact Prostate Cancer Before Choosing a Path

Most prostate cancers are adenocarcinomas, but their behavior varies widely. The pathology report should identify the Gleason patterns and Grade Group, while the clinical stage, PSA level and imaging help estimate whether disease is confined to the prostate, involves nearby lymph nodes or has spread to bone or other organs. Ductal, intraductal, neuroendocrine or small-cell features deserve special attention because they may behave differently.

For localized disease, active surveillance can be appropriate for selected low-risk cancers and is an active medical strategy—not “doing nothing.” Other men benefit from surgery, external-beam radiation, brachytherapy or combinations that may include androgen-deprivation therapy. A thoughtful decision weighs cancer-control benefit against urinary, sexual, bowel, hormonal and cardiovascular effects.

Recurrent and metastatic disease requires a different conversation. A rising PSA after surgery or radiation may still be treatable with salvage therapy. Metastatic hormone-sensitive disease and metastatic castration-resistant disease have expanding systemic and PSMA-directed options. Our broader Stage 4 and metastatic cancer guide explains how advanced disease can remain treatable even when it is not considered curable.

Localized

Active Surveillance

Selected low-risk cancers may be followed with PSA, exams, MRI and repeat biopsy or other testing, with treatment if evidence of progression appears.

Localized or Regional

Curative-Intent Treatment

Surgery, radiation or brachytherapy may be appropriate, sometimes with hormone therapy according to risk and patient priorities.

Biochemical Recurrence

Locate and Characterize

PSA timing, prior pathology, treatment history and modern imaging help determine whether salvage or systemic treatment is reasonable.

Metastatic

Plan the Sequence

Hormonal intensification, chemotherapy, targeted therapy, radiopharmaceuticals, PSMA-directed treatment and trials are considered in context.

Precision Evaluation

PSA Is Important—but It Is Not the Whole Story

A strong review brings together the PSA trend and doubling time, testosterone level when relevant, biopsy or surgical pathology, Grade Group, margins, lymph nodes, MRI, conventional scans, PSMA PET when indicated and every previous treatment with its response and side effects. PSA can be affected by noncancerous conditions, while uncommon aggressive variants may progress with relatively little PSA; results must be interpreted with the clinical picture.

Germline testing should be discussed for men with metastatic, high-risk or very-high-risk disease and for selected men with suggestive family history or pathology. Inherited changes such as BRCA2, BRCA1, ATM, PALB2, CHEK2 and mismatch-repair genes can affect treatment and relatives. Tumor or circulating-tumor DNA testing in advanced disease may identify homologous-recombination repair alterations, MSI-high or mismatch-repair deficiency and other findings that influence targeted therapy or clinical-trial eligibility.

Explore Sunridge cancer diagnostic testing and bring the original reports so useful standard results are not duplicated unnecessarily.

PSMA Has Become Both an Imaging and Treatment Target

PSMA PET can help locate disease, and PSMA-positive cancers may qualify for lutetium Lu 177 vipivotide tetraxetan in defined settings. FDA indications expanded in March 2025 for selected previously treated metastatic castration-resistant disease and again in July 2026, in combination with an androgen-receptor pathway inhibitor, for PSMA-positive metastatic androgen pathway modulation-naïve or sensitive prostate cancer.

Treatment Strategy

Modern Prostate Cancer Care Is a Sequence, Not a Single Decision

Localized care may involve surveillance, prostatectomy, radiation or brachytherapy. Recurrent disease may involve salvage radiation, hormone therapy or metastasis-directed treatment in carefully selected situations. For metastatic hormone-sensitive disease, androgen deprivation is commonly intensified with an androgen-receptor pathway inhibitor and, for some men, chemotherapy or other combinations. Metastatic castration-resistant disease can involve androgen-receptor therapies, taxane chemotherapy, sipuleucel-T for selected patients, radium-223 for particular bone-predominant situations, PARP-inhibitor strategies for certain DNA-repair alterations, PSMA radioligand therapy and clinical trials.

The best next step depends on what has already been used, where the cancer is, how quickly it is changing, symptoms, marrow and organ function, molecular results and the patient’s priorities. A “natural-first” preference deserves a respectful discussion, but no supplement, restrictive diet or infusion has been proven to replace curative treatment for a cancer that needs it or life-prolonging systemic treatment for advanced disease.

Before Local Treatment

Clarify risk, MRI and biopsy findings, expected benefit, urinary baseline, sexual priorities, bowel health and alternatives including surveillance when appropriate.

During Hormone Therapy

Track testosterone and PSA alongside blood pressure, glucose, lipids, body composition, bone density, hot flashes, mood, sleep and sexual health.

After PSA Recurrence

Review PSA kinetics, previous surgery or radiation, pathology, imaging and whether salvage, local or systemic treatment remains possible.

After Progressionn

Reassess histology, PSMA expression, DNA-repair biomarkers, prior sequencing, symptoms and trial eligibility rather than assuming options are exhausted.

Integrative Support

Support Strength, Bone, Metabolic Health and Quality of Life

Oncology team meeting with a prostate cancer patient and partner about treatment and quality of life

A Whole-Person Plan Can Be Measured

Aerobic and resistance exercise adapted to fitness and bone disease
Bone density, vitamin D when indicated, calcium intake and fall risk
Weight, waist, glucose, lipids and cardiovascular risk during ADT
Plant-forward nutrition with adequate protein and individualized calories
Urinary, bowel and sexual rehabilitation after local treatment
Hot flashes, fatigue, sleep, mood, anxiety and cognitive concerns
Pain, neuropathy and mobility when cancer involves bone
Every herb, supplement, hormone product and infusion being used

Exercise is one of the strongest supportive interventions for men receiving androgen-deprivation therapy. Supervised aerobic and resistance programs can improve strength, body composition, fatigue and aspects of quality of life, while also supporting cardiometabolic health. The program must be adapted for anemia, neuropathy, cardiovascular disease, fracture risk and the location of bone metastases.

A practical eating pattern emphasizes vegetables, fruit, legumes, whole grains, nuts, seeds, fish or other appropriate protein sources and minimally processed foods while matching calories to the patient’s needs. Evidence does not support a single “prostate cancer diet.” Lycopene, pomegranate, green tea, soy, selenium, vitamin E and other supplements have been studied, but results are mixed, products vary and some have shown no benefit or potential harm. Food is not automatically medicine, and “natural” does not mean interaction-free.

Safety matters: Tell every treating clinician about supplements and infusions. High-dose antioxidants may be inappropriate around some radiation or chemotherapy schedules; concentrated green-tea extracts can affect the liver; vitamin E and selenium have not prevented prostate cancer and can carry risks; St. John’s wort changes drug metabolism; and products marketed as “testosterone boosters” can be especially concerning in androgen-sensitive disease.

Prepare for Review

What to Send Before a Prostate Cancer Consultation

Helpful records include the biopsy and surgical pathology reports, Gleason patterns and Grade Group, PSA values with dates, prostate MRI, CT, bone scan and PSMA PET reports and images, operative notes, radiation summary and dose, genomic classifiers when performed, and a complete treatment timeline including hormone injections, androgen-receptor drugs, chemotherapy, radiopharmaceuticals and clinical trials.

Please also include germline testing, tumor sequencing or liquid-biopsy results, current PSA and testosterone, blood counts, kidney and liver tests, alkaline phosphatase, glucose or A1c, lipid results, bone-density testing, current medicines and every vitamin, herb, supplement or infusion. We also want to understand urinary and bowel function, sexual health, hot flashes, pain, sleep, activity, mood, caregiver needs and the goals most important now.

Patients comparing cancer types or managing more than one diagnosis can also review our pancreatic cancer treatment guide, cancers treated at Sunridge and cancer treatment resources.

Ask What Records to Send →Speak With Patient Care

Frequently Asked Questions

Questions About Integrative Prostate Cancer Care

Can prostate cancer be watched without immediate treatment?

Yes. Active surveillance is appropriate for selected low-risk and some favorable intermediate-risk cancers, with structured PSA testing, clinical review, MRI and repeat tissue or other assessment. It is different from ignoring the disease and should have clear triggers for intervention.

Can Stage 4 prostate cancer still be treated?

Yes. Metastatic prostate cancer is serious, but many cancers respond to hormone-based and other systemic treatments. Chemotherapy, targeted therapy, PSMA-directed radioligand therapy, bone-directed treatment and trials may apply according to disease state, biomarkers and previous therapy.

Should men with advanced prostate cancer have genetic testing?

Germline testing is recommended or strongly considered in metastatic and selected high-risk situations, and tumor profiling is important in advanced disease. Results can affect PARP-inhibitor strategies, immunotherapy in uncommon MSI-high or mismatch-repair deficient cancers, trial options and relatives’ risk assessment.

Can natural therapies lower PSA or cure prostate cancer?

A PSA change alone does not prove that cancer has been controlled, and no natural therapy has been shown to replace indicated curative or life-prolonging treatment. Integrative care can still be valuable for nutrition, exercise, bone and metabolic health, symptoms, recovery, stress and informed supplement use.

How can I reduce side effects from hormone therapy?

Supervised resistance and aerobic exercise, cardiometabolic risk management, bone-health assessment, adequate protein, healthy weight strategies, sleep and symptom treatment can help. Hot flashes, mood changes, sexual effects and fatigue deserve direct treatment rather than being accepted as inevitable.

Will Sunridge coordinate with my urologist, radiation oncologist or medical oncologist?

Yes. Coordination is important because surgery, radiation, hormone therapy, chemotherapy, PSMA treatments, imaging, medications, supplements and infusions can affect one another. Integrative care should complement—not fragment—the oncology plan.

Primary Sources & Research

References

This page is educational and does not replace diagnosis or treatment advice from a qualified urologist, radiation oncologist, medical oncologist, genetic counselor or multidisciplinary prostate cancer team. Treatment outcomes cannot be guaranteed.

Ready to Discuss Your Situation?

Build a Prostate Cancer Plan Around the Disease and the Whole Person

Our Patient Care Team can explain which records are needed and help determine the next step for a physician-directed integrative prostate cancer consultation.

Request a Prostate Cancer Consultation →Call 1-800-923-7878

Continue learning

Prostate Cancer Articles & Patient Guides

Explore focused articles from the Sunridge research and education library.

August 14, 2026

Prostate Cancer Second Opinion: When and How to Get One

A prostate cancer second opinion can change the diagnosis itself, not just the conversation around treatment. In one…

Read article

July 19, 2026

Integrative Treatment for Prostate Cancer: A Clinical Resource Guide for 2026

The decision to move beyond conventional surgery or radiation is often born from a desire for clinical autonomy…

Read article

View all Prostate Cancer articles →

Cancer care that happens here

Start Here

Cancers We Treat

Treatment & Planning